دورية أكاديمية
أعرض في EDS

Role of prostanoids, nitric oxide and endothelin pathways in pulmonary hypertension due to COPD.

التفاصيل البيبلوغرافية
العنوان: Role of prostanoids, nitric oxide and endothelin pathways in pulmonary hypertension due to COPD.
المؤلفون: Alqarni AA; Department of Respiratory Therapy, Faculty of Medical Rehabilitation Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.; Respiratory Therapy Unit, King Abdulaziz University Hospital, Jeddah, Saudi Arabia., Aldhahir AM; Respiratory Therapy Department, Faculty of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia., Alghamdi SA; Respiratory Care Department, Al Murjan Hospital, Jeddah, Saudi Arabia., Alqahtani JS; Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dammam, Saudi Arabia., Siraj RA; Department of Respiratory Care, College of Applied Medical Sciences, King Faisal University, Al Ahsa, Saudi Arabia., Alwafi H; Faculty of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia., AlGarni AA; King Abdulaziz Hospital, The Ministry of National Guard Health Affairs, Al Ahsa, Saudi Arabia.; King Saud bin Abdulaziz University for Health Sciences, College of Applied Medical Sciences, Al Ahsa, Saudi Arabia., Majrshi MS; National Heart and Lung Institute, Imperial College London, London, United Kingdom.; Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom., Alshehri SM; Department of Respiratory Therapy, King Fahad General Hospital, Jeddah, Saudi Arabia., Pang L; Respiratory Medicine Research Group, Academic Unit for Translational Medical Sciences, University of Nottingham School of Medicine, Nottingham, United Kingdom.
المصدر: Frontiers in medicine [Front Med (Lausanne)] 2023 Oct 10; Vol. 10, pp. 1275684. Date of Electronic Publication: 2023 Oct 10 (Print Publication: 2023).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Lausanne, Switzerland : Frontiers Media S.A., [2014]-
مستخلص: Pulmonary hypertension (PH) due to chronic obstructive pulmonary disease (COPD) is classified as Group 3 PH, with no current proven targeted therapies. Studies suggest that cigarette smoke, the most risk factor for COPD can cause vascular remodelling and eventually PH as a result of dysfunction and proliferation of pulmonary artery smooth muscle cells (PASMCs) and pulmonary artery endothelial cells (PAECs). In addition, hypoxia is a known driver of pulmonary vascular remodelling in COPD, and it is also thought that the presence of hypoxia in patients with COPD may further exaggerate cigarette smoke-induced vascular remodelling; however, the underlying cause is not fully understood. Three main pathways (prostanoids, nitric oxide and endothelin) are currently used as a therapeutic target for the treatment of patients with different groups of PH. However, drugs targeting these three pathways are not approved for patients with COPD-associated PH due to lack of evidence. Thus, this review aims to shed light on the role of impaired prostanoids, nitric oxide and endothelin pathways in cigarette smoke- and hypoxia-induced pulmonary vascular remodelling and also discusses the potential of using these pathways as therapeutic target for patients with PH secondary to COPD.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Alqarni, Aldhahir, Alghamdi, Alqahtani, Siraj, Alwafi, AlGarni, Majrshi, Alshehri and Pang.)
References: N Engl J Med. 1992 Jul 9;327(2):70-5. (PMID: 1603138)
Mol Cell Biochem. 2010 Jan;333(1-2):191-201. (PMID: 19618122)
J Am Coll Cardiol. 2003 Apr 16;41(8):1380-6. (PMID: 12706935)
Eur Respir J. 2007 Aug;30(2):364-72. (PMID: 17666559)
Cell Tissue Res. 2017 Mar;367(3):643-649. (PMID: 28025704)
PLoS One. 2014 Jun 06;9(6):e98532. (PMID: 24906007)
Am J Physiol. 1995 Aug;269(2 Pt 1):L215-20. (PMID: 7653583)
Circulation. 2013 Jan 15;127(2):233-43. (PMID: 23204105)
Am J Physiol Lung Cell Mol Physiol. 2009 Apr;296(4):L648-56. (PMID: 19201816)
J Appl Physiol (1985). 2006 Feb;100(2):672-8. (PMID: 16210440)
Arch Immunol Ther Exp (Warsz). 2015 Feb;63(1):41-52. (PMID: 25288367)
Biochem Biophys Res Commun. 2005 Dec 9;338(1):45-52. (PMID: 16115610)
Ann Intern Med. 2005 Aug 16;143(4):282-92. (PMID: 16103472)
Am J Respir Crit Care Med. 2002 Mar 15;165(6):800-4. (PMID: 11897647)
Nature. 1976 Jun 17;261(5561):558-60. (PMID: 934294)
Chin Med J (Engl). 2010 Dec;123(24):3663-70. (PMID: 22166648)
Cardiovasc Res. 2004 Feb 1;61(2):227-37. (PMID: 14736539)
Pulm Med. 2012;2012:203952. (PMID: 22973510)
J Tongji Med Univ. 1989;9(3):148-52. (PMID: 2513417)
Am J Physiol Lung Cell Mol Physiol. 2001 Aug;281(2):L403-11. (PMID: 11435215)
N Engl J Med. 2021 Jan 28;384(4):325-334. (PMID: 33440084)
Am J Respir Crit Care Med. 2002 Aug 1;166(3):314-22. (PMID: 12153963)
J Cell Mol Med. 2012 Aug;16(8):1840-55. (PMID: 22050691)
N Engl J Med. 1993 Jun 17;328(24):1732-9. (PMID: 8497283)
J Biol Chem. 2003 Sep 26;278(39):37937-47. (PMID: 12835322)
Am Rev Respir Dis. 1983 Oct;128(4):702-7. (PMID: 6625346)
Am J Respir Crit Care Med. 2004 Nov 15;170(10):1101-7. (PMID: 15317671)
J Biol Chem. 1997 Jan 3;272(1):601-8. (PMID: 8995303)
J Heart Lung Transplant. 2021 Sep;40(9):1009-1018. (PMID: 34218966)
Eur Respir J. 2011 Sep;38(3):617-27. (PMID: 21310874)
Naunyn Schmiedebergs Arch Pharmacol. 2008 Sep;378(3):241-51. (PMID: 18542928)
Science. 1976 Sep 17;193(4258):1135-7. (PMID: 959827)
J Clin Invest. 1999 Jun;103(11):1509-15. (PMID: 10359560)
Int J Mol Sci. 2018 Aug 12;19(8):. (PMID: 30103548)
Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L548-54. (PMID: 17526595)
Am J Respir Crit Care Med. 2015 Apr 1;191(7):e4-e27. (PMID: 25830527)
Curr Opin Pulm Med. 2023 Sep 1;29(5):370-379. (PMID: 37395513)
Respir Res. 2022 May 28;23(1):136. (PMID: 35643499)
Lancet. 2008 Jun 21;371(9630):2093-100. (PMID: 18572079)
Am J Respir Crit Care Med. 2001 Aug 15;164(4):709-13. (PMID: 11520741)
Mol Biol Rep. 2012 Dec;39(12):10447-57. (PMID: 23053949)
Am J Physiol. 1998 Jun;274(6):L908-13. (PMID: 9609729)
Eur Respir J. 2015 Aug;46(2):346-54. (PMID: 25929951)
Eur Respir J. 2016 Oct;48(4):1137-1149. (PMID: 27471204)
Lung. 1992;170(2):109-24. (PMID: 1501507)
Eur Respir J. 2008 Nov;32(5):1371-85. (PMID: 18978137)
Eur Heart J. 2016 Jan 1;37(1):67-119. (PMID: 26320113)
Circ J. 2010 May;74(5):836-43. (PMID: 20424334)
N Engl J Med. 1972 Apr 27;286(17):912-8. (PMID: 5013974)
Eur Respir J. 2003 May;21(5):892-905. (PMID: 12765440)
Am J Respir Crit Care Med. 2010 Feb 1;181(3):270-8. (PMID: 19875684)
Am J Respir Crit Care Med. 1997 Dec;156(6):1794-9. (PMID: 9412557)
Mol Cell Biochem. 2000 May;208(1-2):53-62. (PMID: 10939628)
Cardiovasc Res. 1999 Aug 15;43(3):580-94. (PMID: 10690330)
Vet Immunol Immunopathol. 2017 Oct;192:33-40. (PMID: 29042013)
J Heart Lung Transplant. 2010 Feb;29(2):137-49. (PMID: 20022264)
N Engl J Med. 1995 Jul 27;333(4):214-21. (PMID: 7540722)
Am J Physiol. 1996 May;270(5 Pt 1):L872-8. (PMID: 8967523)
Cardiovasc Res. 2010 Feb 1;85(3):582-92. (PMID: 19710084)
Saudi Med J. 2016 May;37(5):498-505. (PMID: 27146611)
J Am Coll Cardiol. 2002 May 1;39(9):1496-502. (PMID: 11985913)
Eurasian J Med. 2020 Jun;52(2):166-170. (PMID: 32612425)
Annu Rev Biochem. 2000;69:145-82. (PMID: 10966456)
Cancer Res. 1996 Oct 1;56(19):4424-9. (PMID: 8813136)
Eur Respir J. 2002 Apr;19(4):632-8. (PMID: 11998991)
Eur Respir J. 2008 Sep;32(3):619-28. (PMID: 18448495)
Circulation. 2003 Jul 1;107(25):3230-5. (PMID: 12796132)
Herz. 1992 Oct;17(5):291-9. (PMID: 1335437)
Eur Respir J. 2002 Aug;20(2):332-8. (PMID: 12212964)
Expert Rev Respir Med. 2021 Jan;15(1):51-58. (PMID: 33191816)
Front Med (Lausanne). 2023 Aug 29;10:1217156. (PMID: 37706024)
Lancet. 2001 Oct 6;358(9288):1119-23. (PMID: 11597664)
Crit Care. 2001 Dec;5(6):286-9. (PMID: 11737906)
Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):10-3. (PMID: 21801847)
Medicina (Kaunas). 2023 Jan 13;59(1):. (PMID: 36676790)
Hypertension. 2018 Jan;71(1):34-55. (PMID: 29158355)
Am J Kidney Dis. 2020 Jun;75(6):935-945. (PMID: 32199709)
Circulation. 2002 Jul 2;106(1):57-62. (PMID: 12093770)
Tex Heart Inst J. 2010;37(4):391-9. (PMID: 20844610)
ERJ Open Res. 2022 Feb 21;8(1):. (PMID: 35198628)
Am J Transl Res. 2017 Sep 15;9(9):3967-3976. (PMID: 28979673)
Eur Respir Rev. 2015 Dec;24(138):630-41. (PMID: 26621977)
Vasc Health Risk Manag. 2007;3(1):11-22. (PMID: 17583171)
Mol Pharmacol. 1995 Nov;48(5):890-6. (PMID: 7476920)
Can J Physiol Pharmacol. 2008 Aug;86(8):516-25. (PMID: 18758499)
Eur Respir J. 2008 Apr;31(4):891-901. (PMID: 18378784)
Respirology. 2008 Nov;13(7):1014-21. (PMID: 18699805)
Curr Drug Targets. 2011 Apr;12(4):501-13. (PMID: 21194405)
Front Pharmacol. 2019 Jan 18;9:1518. (PMID: 30713496)
Circulation. 2014 Dec 9;130(24):2189-208. (PMID: 25602947)
J Thorac Dis. 2017 Jan;9(1):30-41. (PMID: 28203404)
Contemp Clin Trials. 2011 Mar;32(2):280-7. (PMID: 21146637)
Eur Respir J. 2023 Jan 6;61(1):. (PMID: 36028254)
Am J Respir Crit Care Med. 2005 Jul 15;172(2):189-94. (PMID: 15831842)
Circulation. 2001 Jul 24;104(4):424-8. (PMID: 11468204)
Am J Respir Cell Mol Biol. 2012 Apr;46(4):431-6. (PMID: 22033266)
Drugs. 2009 Jun 18;69(9):1153-71. (PMID: 19537834)
J Immunol. 2010 Jan 1;184(1):433-41. (PMID: 20028661)
Heart Vessels. 2018 Nov;33(11):1411-1422. (PMID: 29796776)
Int J Chron Obstruct Pulmon Dis. 2018 Apr 13;13:1177-1186. (PMID: 29695901)
Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L717-25. (PMID: 12225948)
N Engl J Med. 2002 Mar 21;346(12):896-903. (PMID: 11907289)
J Biol Chem. 1998 Aug 21;273(34):22120-7. (PMID: 9705357)
Thorax. 2005 Jul;60(7):605-9. (PMID: 15994270)
Life Sci. 2012 Oct 15;91(13-14):607-12. (PMID: 22406300)
Nature. 1988 Mar 31;332(6163):411-5. (PMID: 2451132)
Eur Respir J. 2012 Oct;40(4):874-80. (PMID: 22362844)
Int J Clin Exp Med. 2009;2(1):87-94. (PMID: 19436835)
Oxid Med Cell Longev. 2016;2016:5249086. (PMID: 27594972)
Respir Res. 2001;2(2):90-101. (PMID: 11686871)
Mayo Clin Proc. 2020 Sep;95(9):1978-1988. (PMID: 32861339)
Am Heart J. 2014 Feb;167(2):210-7. (PMID: 24439982)
Eur Respir J. 2023 Jul 20;62(1):. (PMID: 37414421)
Ther Adv Respir Dis. 2009 Feb;3(1):15-21. (PMID: 19293199)
Mol Pharmacol. 2002 Nov;62(5):1147-53. (PMID: 12391278)
BMJ. 2020 Feb 19;368:m234. (PMID: 32075787)
Respir Res. 2022 Dec 15;23(1):349. (PMID: 36522710)
Am J Respir Cell Mol Biol. 2002 Dec;27(6):688-96. (PMID: 12444028)
COPD. 2012 Jun;9(3):268-75. (PMID: 22360383)
Biochem Biophys Res Commun. 2007 Nov 23;363(3):656-61. (PMID: 17904526)
Thorax. 1981 Oct;36(10):752-8. (PMID: 7330793)
Am J Respir Crit Care Med. 2007 Apr 1;175(7):676-85. (PMID: 17255567)
Int J Chron Obstruct Pulmon Dis. 2016 Jul 05;11:1533-41. (PMID: 27462149)
Acta Physiol (Oxf). 2012 Aug;205(4):507-19. (PMID: 22554045)
Ann Intern Med. 1991 Mar 15;114(6):464-9. (PMID: 1994793)
Am J Respir Cell Mol Biol. 2010 Dec;43(6):629-34. (PMID: 20008280)
FASEB J. 2001 Feb;15(2):427-38. (PMID: 11156958)
J Clin Invest. 2020 Nov 2;130(11):5638-5651. (PMID: 32881714)
Cardiovasc Res. 2018 Mar 15;114(4):529-539. (PMID: 29394331)
J Appl Physiol (1985). 1994 May;76(5):1976-82. (PMID: 8063659)
Respir Res. 2007 Nov 01;8:77. (PMID: 17974037)
Pathol Res Pract. 2020 Sep;216(9):153083. (PMID: 32825951)
Am J Respir Crit Care Med. 2002 Feb 1;165(3):398-405. (PMID: 11818328)
Am J Respir Crit Care Med. 2018 Oct 15;198(8):1000-1011. (PMID: 29746142)
Core Evid. 2007 Nov 30;2(2):131-50. (PMID: 21221181)
Biomedicines. 2021 Jan 09;9(1):. (PMID: 33435311)
Respir Investig. 2019 Jul;57(4):325-329. (PMID: 31085118)
Pharmacol Rev. 2012 Jul;64(3):540-82. (PMID: 22679221)
FASEB J. 2005 Jul;19(9):1178-80. (PMID: 15897232)
Am J Respir Crit Care Med. 2003 Mar 1;167(5):735-40. (PMID: 12480614)
Prostaglandins Other Lipid Mediat. 2018 Jan;134:32-37. (PMID: 29180071)
Eur Respir J. 2006 Mar;27(3):578-84. (PMID: 16507859)
Eur Heart J. 2022 Oct 11;43(38):3618-3731. (PMID: 36017548)
Eur Respir Rev. 2014 Sep;23(133):350-5. (PMID: 25176971)
Br J Pharmacol. 2010 Dec;161(7):1599-615. (PMID: 20698855)
J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):56S-61S. (PMID: 15194179)
Eur Respir J. 2019 Jun 27;53(6):. (PMID: 30956210)
Am J Physiol. 1998 Apr;274(4):L517-26. (PMID: 9575869)
Eur Respir J. 2013 Oct;42(4):982-92. (PMID: 23429918)
J Biol Chem. 2000 May 19;275(20):15314-20. (PMID: 10809766)
Chest. 2005 May;127(5):1531-6. (PMID: 15888824)
J Biol Chem. 2004 Dec 17;279(51):53036-47. (PMID: 15471868)
J Lipid Res. 2011 Apr;52(4):720-31. (PMID: 21296955)
Adv Exp Med Biol. 2021;1303:209-241. (PMID: 33788196)
Pulm Circ. 2012 Apr-Jun;2(2):193-200. (PMID: 22837860)
Proc Am Thorac Soc. 2005;2(4):258-66; discussion 290-1. (PMID: 16267346)
J Cardiovasc Pharmacol Ther. 2021 Sep;26(5):453-462. (PMID: 33836637)
Eur J Pharmacol. 2013 Mar 5;703(1-3):11-7. (PMID: 23399768)
J Appl Physiol (1985). 2005 Mar;98(3):1111-8; discussion 1091. (PMID: 15516370)
J Clin Invest. 1994 Feb;93(2):493-8. (PMID: 8113389)
Eur Respir J. 2017 Jul 20;50(1):. (PMID: 28729479)
Cardiovasc Res. 2001 Jan;49(1):200-6. (PMID: 11121812)
Eur Respir J. 2008 Apr;31(4):759-64. (PMID: 18094009)
J Healthc Eng. 2022 Feb 10;2022:3247807. (PMID: 35186226)
N Engl J Med. 2002 Aug 1;347(5):322-9. (PMID: 12151469)
Int J Chron Obstruct Pulmon Dis. 2020 Jun 09;15:1315-1324. (PMID: 32606641)
Am Rev Respir Dis. 1993 Aug;148(2):310-6. (PMID: 8342892)
J Vasc Res. 2011;48(6):465-75. (PMID: 21691120)
Pulm Circ. 2013 Jan;3(1):20-30. (PMID: 23662172)
Dev Biol. 2018 Dec 1;444 Suppl 1:S156-S169. (PMID: 30171849)
Am Rev Respir Dis. 1984 Dec;130(6):993-8. (PMID: 6439091)
Br J Pharmacol. 2021 Jan;178(1):132-151. (PMID: 31976545)
J Clin Invest. 1993 Apr;91(4):1367-73. (PMID: 7682570)
Sci Rep. 2015 Nov 27;5:17376. (PMID: 26611322)
Respiration. 1991;58(5-6):304-10. (PMID: 1792422)
Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):1877-85. (PMID: 17541026)
Eur Respir J. 2012 Apr;39(4):927-38. (PMID: 21828025)
فهرسة مساهمة: Keywords: COPD; COPD-associated pulmonary hypertension; endothelin; nitric oxide; prostanoid; pulmonary hypertension; pulmonary hypertension in COPD; type 3 pulmonary hypertension
تواريخ الأحداث: Date Created: 20231026 Latest Revision: 20231027
رمز التحديث: 20231027
مُعرف محوري في PubMed: PMC10597708
DOI: 10.3389/fmed.2023.1275684
PMID: 37881627
قاعدة البيانات: MEDLINE
الوصف
تدمد:2296-858X
DOI:10.3389/fmed.2023.1275684